Young patients with chronic ITP may experience relapse within 5 years of completing therapy. In this study, investigators sought to determine if the 4R+3Dex regimen for chronic ITP would improve response rates in pediatric patients with the disease.
Results of a retrospective single-center study showed that response to rituximab vs splenectomy as second-line therapy for steroid-refractory ITP was not significantly different between the 2 treatments.
A rare case of Langerhans cell histiocytosis (LCH) in a patient with idiopathic thrombocytopenic purpura (ITP) highlights the difficulty in diagnosing LCH.
This fact sheet examines immune thrombocytopenia (ITP), including patient outlook, treatment, and ITP in pregnancy.
Recent study results demonstrate that recombinant IL-11 with glucocorticoids is a safe and effective treatment for idiopathic thrombocytopenic purpura (ITP) in adults.
Approximately 40% of ITP cases are caused by gram-negative H pylori infection; therefore, researchers sought to determine the effectiveness of infection eradication on platelet count in these patients.
